PLRZ (polyrizon-biotech.com) יחס שווי שוק לשווי בספרים

Polyrizon Ltd (PLRZ) is developing the Capture and Confine nasal barrier system to block pathogens. The price-to-book ratio visualizes asset value dynamics, where 0.77 indicates the level of this metric. However, geopolitics complicates raw material logistics and patent protection. The company's environmental profile remains neutral, relying on standard biomaterial disposal.

The metric is calculated as the quotient of the total market capitalization divided by the net asset value. It determines the degree of business overvaluation relative to its actual tangible resources. For Polyrizon Ltd (PLRZ), this gap is driven by expectations regarding the commercialization of nasal sprays and a reliance on grants. Investors should evaluate the price-to-book ratio as an indicator of speculative potential. High values on this chart signal risks of a correction.